Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential tazarotene gel versus continued tazarotene/betamethasone cream in chronic plaque psoriasis
ChiCTR1900027060Phase 4Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tazarotene and betamethasone dipropionate in psoriasis (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Percentage reduction in PASI from baseline after 4 weeks of randomized treatment. Started Mar 2017; status: completed.
02
Drugs
tazarotenebetamethasone dipropionate
03
Conditions
psoriasis
Beyond the preview
Go deeper on ChiCTR1900027060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027060.